The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York HIMS: Regulatory Arbitrage and the Future of Personalized Medicine FDA Proposes to Exclude GLP 1s From 503B Bulk List Drug Topics Peptide Therapy in Austin, TX Austin Plastic Surgeon Dr. Chuma